Sign In
Buy RLFTY
$0.423
+0 (+0%)
At Close: Jun 03, 2026
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
02:15am, Friday, 15'th Sep 2023
GENEVA, SWITZERLAND / ACCESSWIRE / September 15, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
03:15am, Friday, 01'st Sep 2023
GENEVA, SWITZERLAND / ACCESSWIRE / September 1, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering inn
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
02:00am, Wednesday, 19'th Jul 2023
Recent Pentech Health acquisition of ZOIA Pharma broadens distribution and access for patients to PKU GOLIKE® GENEVA, SWITZERLAND / ACCESSWIRE / July 19, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RL
The results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomimic Technology™ GENEVA, SWITZERLAND / ACCESSWIRE
FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate
01:21pm, Tuesday, 21'st Jun 2022
The FDA issued a Complete Response Letter regarding the marketing application for Acer Therapeutics Inc (NASDAQ: ACER) and its collaboration partner, Relief Therapeutics Holding SA's (OTC: RLFTF
